Lower-Limb Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major lower-limb spasticity markets are expected to exhibit a CAGR of 6.98% during 2024-2034.
The lower-limb spasticity market has been comprehensively analyzed in IMARC's new report titled "Lower-Limb Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034. Lower-limb spasticity refers to a neurological condition characterized by increased muscle tone and involuntary muscle contractions in the muscles of the lower extremities, including the legs and feet. It is often a result of damage to the central nervous system, mainly the spinal cord and brain. The symptoms of the illness can vary in intensity, ranging from mild muscle stiffness to severe spasms. Individuals suffering from the ailment may experience difficulties with movement, walking, and maintaining proper posture. In a few cases, this condition can also lead to muscle imbalances and joint deformities, which can further impede mobility and reduce the overall quality of life. The diagnosis of lower-limb spasticity typically involves a thorough clinical evaluation by a healthcare professional, such as a neurologist or a physiatrist. The diagnostic process may include assessing the patient's medical history, conducting physical examinations, and evaluating muscle tone, reflexes, and motor function using specialized tests.
The increasing cases of cerebral palsy, which cause disruptions in the normal functioning of the central nervous system, are primarily driving the lower-limb spasticity market. In addition to this, the inflating utilization of rehabilitative techniques, such as occupational and physical therapies is also creating a positive outlook for the market. These interventions focus on enhancing muscle flexibility, refining coordination, and bolstering gross motor skills in individuals suffering from the disorder. Moreover, the widespread adoption of potent medications, including botulinum toxins, baclofen, tizanidine, etc., to alleviate symptoms and improve patient mobility is further propelling the market growth. Apart from this, the rising usage of cutting-edge technologies like neuromodulation techniques, intrathecal drug delivery systems, and electrical stimulation methods, since they work by directly influencing neural pathways responsible for spasticity, thereby offering localized and sustained relief, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy as an innovative approach to rectify underlying genetic anomalies responsible for the disease is also augmenting the market growth. Furthermore, the escalating demand for stem cell therapy and neuroregenerative treatments, aiming to repair or replace damaged nerve tissues contributing to the condition is expected to drive the lower-limb spasticity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the lower-limb spasticity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lower-limb spasticity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lower-limb spasticity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lower-limb spasticity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lower-limb spasticity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lower-limb spasticity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the lower-limb spasticity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lower-limb spasticity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lower-limb spasticity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of lower-limb spasticity across the seven major markets?
What is the number of prevalent cases (2018-2034) of lower-limb spasticity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of lower-limb spasticity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with lower-limb spasticity across the seven major markets?
What is the size of the lower-limb spasticity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lower-limb spasticity?
What will be the growth rate of patients across the seven major markets?
Lower-Limb Spasticity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lower-limb spasticity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lower-limb spasticity market?
What are the key regulatory events related to the lower-limb spasticity market?
What is the structure of clinical trial landscape by status related to the lower-limb spasticity market?
What is the structure of clinical trial landscape by phase related to the lower-limb spasticity market?
What is the structure of clinical trial landscape by route of administration related to the lower-limb spasticity market?
The lower-limb spasticity market has been comprehensively analyzed in IMARC's new report titled "Lower-Limb Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034. Lower-limb spasticity refers to a neurological condition characterized by increased muscle tone and involuntary muscle contractions in the muscles of the lower extremities, including the legs and feet. It is often a result of damage to the central nervous system, mainly the spinal cord and brain. The symptoms of the illness can vary in intensity, ranging from mild muscle stiffness to severe spasms. Individuals suffering from the ailment may experience difficulties with movement, walking, and maintaining proper posture. In a few cases, this condition can also lead to muscle imbalances and joint deformities, which can further impede mobility and reduce the overall quality of life. The diagnosis of lower-limb spasticity typically involves a thorough clinical evaluation by a healthcare professional, such as a neurologist or a physiatrist. The diagnostic process may include assessing the patient's medical history, conducting physical examinations, and evaluating muscle tone, reflexes, and motor function using specialized tests.
The increasing cases of cerebral palsy, which cause disruptions in the normal functioning of the central nervous system, are primarily driving the lower-limb spasticity market. In addition to this, the inflating utilization of rehabilitative techniques, such as occupational and physical therapies is also creating a positive outlook for the market. These interventions focus on enhancing muscle flexibility, refining coordination, and bolstering gross motor skills in individuals suffering from the disorder. Moreover, the widespread adoption of potent medications, including botulinum toxins, baclofen, tizanidine, etc., to alleviate symptoms and improve patient mobility is further propelling the market growth. Apart from this, the rising usage of cutting-edge technologies like neuromodulation techniques, intrathecal drug delivery systems, and electrical stimulation methods, since they work by directly influencing neural pathways responsible for spasticity, thereby offering localized and sustained relief, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy as an innovative approach to rectify underlying genetic anomalies responsible for the disease is also augmenting the market growth. Furthermore, the escalating demand for stem cell therapy and neuroregenerative treatments, aiming to repair or replace damaged nerve tissues contributing to the condition is expected to drive the lower-limb spasticity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the lower-limb spasticity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lower-limb spasticity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lower-limb spasticity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the lower-limb spasticity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the lower-limb spasticity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current lower-limb spasticity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the lower-limb spasticity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the lower-limb spasticity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the lower-limb spasticity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of lower-limb spasticity across the seven major markets?
What is the number of prevalent cases (2018-2034) of lower-limb spasticity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of lower-limb spasticity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with lower-limb spasticity across the seven major markets?
What is the size of the lower-limb spasticity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of lower-limb spasticity?
What will be the growth rate of patients across the seven major markets?
Lower-Limb Spasticity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for lower-limb spasticity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lower-limb spasticity market?
What are the key regulatory events related to the lower-limb spasticity market?
What is the structure of clinical trial landscape by status related to the lower-limb spasticity market?
What is the structure of clinical trial landscape by phase related to the lower-limb spasticity market?
What is the structure of clinical trial landscape by route of administration related to the lower-limb spasticity market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LOWER-LIMB SPASTICITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LOWER-LIMB SPASTICITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LOWER-LIMB SPASTICITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 LOWER-LIMB SPASTICITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LOWER-LIMB SPASTICITY - UNMET NEEDS
10 LOWER-LIMB SPASTICITY - KEY ENDPOINTS OF TREATMENT
11 LOWER-LIMB SPASTICITY - MARKETED PRODUCTS
11.1 List of Lower-Limb Spasticity Marketed Drugs Across the Top 7 Markets
11.1.1 Dysport (Abobotulinumtoxina) - Ipsen Biopharm
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LOWER-LIMB SPASTICITY - PIPELINE DRUGS
12.1 List of Lower-Limb Spasticity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 LOWER-LIMB SPASTICITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 LOWER-LIMB SPASTICITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LOWER-LIMB SPASTICITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Lower-Limb Spasticity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Lower-Limb Spasticity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Lower-Limb Spasticity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Lower-Limb Spasticity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Lower-Limb Spasticity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Lower-Limb Spasticity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Lower-Limb Spasticity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Lower-Limb Spasticity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Lower-Limb Spasticity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Lower-Limb Spasticity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Lower-Limb Spasticity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Lower-Limb Spasticity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Lower-Limb Spasticity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Lower-Limb Spasticity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Lower-Limb Spasticity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Lower-Limb Spasticity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Lower-Limb Spasticity - Access and Reimbursement Overview
16 LOWER-LIMB SPASTICITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LOWER-LIMB SPASTICITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LOWER-LIMB SPASTICITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LOWER-LIMB SPASTICITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LOWER-LIMB SPASTICITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LOWER-LIMB SPASTICITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 LOWER-LIMB SPASTICITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LOWER-LIMB SPASTICITY - UNMET NEEDS
10 LOWER-LIMB SPASTICITY - KEY ENDPOINTS OF TREATMENT
11 LOWER-LIMB SPASTICITY - MARKETED PRODUCTS
11.1 List of Lower-Limb Spasticity Marketed Drugs Across the Top 7 Markets
11.1.1 Dysport (Abobotulinumtoxina) - Ipsen Biopharm
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LOWER-LIMB SPASTICITY - PIPELINE DRUGS
12.1 List of Lower-Limb Spasticity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 LOWER-LIMB SPASTICITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 LOWER-LIMB SPASTICITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LOWER-LIMB SPASTICITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Lower-Limb Spasticity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Lower-Limb Spasticity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Lower-Limb Spasticity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Lower-Limb Spasticity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Lower-Limb Spasticity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Lower-Limb Spasticity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Lower-Limb Spasticity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Lower-Limb Spasticity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Lower-Limb Spasticity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Lower-Limb Spasticity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Lower-Limb Spasticity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Lower-Limb Spasticity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Lower-Limb Spasticity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Lower-Limb Spasticity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Lower-Limb Spasticity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Lower-Limb Spasticity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Lower-Limb Spasticity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Lower-Limb Spasticity - Access and Reimbursement Overview
16 LOWER-LIMB SPASTICITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LOWER-LIMB SPASTICITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LOWER-LIMB SPASTICITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
